UY33528A - Derivados de oxadiazoles y de piridazinas, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de oxadiazoles y de piridazinas, su preparacion y su aplicacion en terapeutica

Info

Publication number
UY33528A
UY33528A UY0001033528A UY33528A UY33528A UY 33528 A UY33528 A UY 33528A UY 0001033528 A UY0001033528 A UY 0001033528A UY 33528 A UY33528 A UY 33528A UY 33528 A UY33528 A UY 33528A
Authority
UY
Uruguay
Prior art keywords
therapeutics
application
piridazines
oxadiazols
derivatives
Prior art date
Application number
UY0001033528A
Other languages
English (en)
Inventor
Claudie Namane
Christophe Philippo
Eykmar Fett
Patrick Mougenot
Eric Nicolai
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY33528A publication Critical patent/UY33528A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)

Abstract

La invención se refiere a los compuestos de fórmula (1) en la que n, D, W ,X1 ,X2 , X3 R1, R2, Y, Z1, Z2 y Z3 son tales como se ha definido en la descripción. La invención se refiere igualmente a un procedimiento de preparación de los compuestos de fórmula (1), de las composiciones que los contienen y a su aplicación en terapéutica.
UY0001033528A 2010-07-23 2011-07-22 Derivados de oxadiazoles y de piridazinas, su preparacion y su aplicacion en terapeutica UY33528A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1056060A FR2963005B1 (fr) 2010-07-23 2010-07-23 Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
UY33528A true UY33528A (es) 2012-02-29

Family

ID=43416427

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033528A UY33528A (es) 2010-07-23 2011-07-22 Derivados de oxadiazoles y de piridazinas, su preparacion y su aplicacion en terapeutica

Country Status (16)

Country Link
US (1) US20130137691A1 (es)
EP (1) EP2595970B1 (es)
JP (1) JP2013532655A (es)
KR (1) KR20130041127A (es)
CN (1) CN103201271A (es)
AR (1) AR088021A1 (es)
AU (1) AU2011281173A1 (es)
BR (1) BR112013001534A2 (es)
CA (1) CA2806271A1 (es)
FR (1) FR2963005B1 (es)
MX (1) MX2013000907A (es)
RU (1) RU2013107759A (es)
SG (1) SG187564A1 (es)
TW (1) TW201206442A (es)
UY (1) UY33528A (es)
WO (1) WO2012011081A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202110242YA (en) * 2015-09-16 2021-10-28 Metacrine Inc Farnesoid x receptor agonists and uses thereof
CN107651722A (zh) * 2016-07-24 2018-02-02 天津师范大学 基于3‑(5‑甲基‑1,3,4‑噁二唑)吡啶的三氟甲磺酸‑Ag(I)配合物在吸附染料中的应用
CN107662956A (zh) * 2016-07-28 2018-02-06 天津师范大学 3‑(5‑甲基‑1,3,4‑噁二唑)吡啶配体构筑的六氟磷酸‑Ag(I)配合物在吸附染料中的应用
US10961198B2 (en) 2017-03-15 2021-03-30 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
CA3056019A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
CN113056271A (zh) 2018-09-18 2021-06-29 梅塔科林公司 法尼醇x受体激动剂及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
FR2840301B1 (fr) 2002-05-29 2007-03-23 Sanofi Synthelabo Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique
GB0427328D0 (en) * 2004-12-14 2005-01-19 Astrazeneca Ab Chemical compounds
CA2651663A1 (en) * 2006-05-30 2007-12-06 Astrazeneca Ab Chemical compounds
US8084478B2 (en) * 2006-05-30 2011-12-27 Asstrazeneca Ab Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase
GB0611507D0 (en) * 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611552D0 (en) * 2006-06-12 2006-07-19 Astrazeneca Ab Chemical compounds
JP2010536839A (ja) * 2007-08-17 2010-12-02 アストラゼネカ アクチボラグ 化合物９７９
CA2719721C (en) * 2008-03-26 2012-12-18 Daiichi Sankyo Company, Limited Tetrahydroisoquinoline derivative
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
JP2010132590A (ja) * 2008-12-03 2010-06-17 Astellas Pharma Inc オキサジアゾール化合物
MX2011006672A (es) * 2008-12-19 2011-07-20 Astrazeneca Ab Derivados de 1,3,4-oxadiazol y sus usos para tratar diabetes.
CN102365273A (zh) * 2009-01-28 2012-02-29 赛诺菲 噻二唑与*二唑衍生物及其制备与其治疗用途
FR2941457A1 (fr) * 2009-01-28 2010-07-30 Sanofi Aventis Derives de thiadiazoles et d'oxadiazoles leur preparation et leur application en therapeutique
US8637507B2 (en) * 2009-03-18 2014-01-28 Merck Sharp & Dohme Corp. Bicyclic compounds as inhibitors of diacylglycerol acyltransferase

Also Published As

Publication number Publication date
AU2011281173A1 (en) 2013-02-07
US20130137691A1 (en) 2013-05-30
CA2806271A1 (en) 2012-01-26
TW201206442A (en) 2012-02-16
BR112013001534A2 (pt) 2016-05-10
FR2963005B1 (fr) 2012-08-17
FR2963005A1 (fr) 2012-01-27
JP2013532655A (ja) 2013-08-19
EP2595970A1 (en) 2013-05-29
EP2595970B1 (en) 2015-01-07
KR20130041127A (ko) 2013-04-24
AR088021A1 (es) 2014-05-07
RU2013107759A (ru) 2014-08-27
SG187564A1 (en) 2013-03-28
WO2012011081A1 (en) 2012-01-26
MX2013000907A (es) 2013-03-05
CN103201271A (zh) 2013-07-10

Similar Documents

Publication Publication Date Title
UY31367A1 (es) Derivados de nicotinamida, su preparacion y su aplicacion en terapeutica
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
UY33427A (es) Derivados de carbamatos de hexafluoroisopropilo, su preparacion y su aplicacion en terapeutica
CO6650360A2 (es) Derivados de imidazopiridina, su procedimiento de preparació;n y su aplicación en terapéutica
ECSP14013222A (es) Indazoles
CR20120264A (es) Compuestos
EA201690312A1 (ru) Улучшенная липидная композиция
DOP2012000321A (es) Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeutica
IN2014MN02598A (es)
NI201100011A (es) Derivados de piridino - piridinonas, su preparación y su aplicación en terapéutica.
ECSP14013327A (es) Compuestos con actividad nematicida
IN2014CN04530A (es)
UY32517A (es) Derivados de nicotinamida, su preparación y su aplicación en terapéutica
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
CR20130671A (es) Antagonistas de trpv4
UY33528A (es) Derivados de oxadiazoles y de piridazinas, su preparacion y su aplicacion en terapeutica
UY32553A (es) Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos
EA201491195A1 (ru) Способ получения композиции, содержащей галактоолигосахариды
SV2009003429A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
UY33415A (es) Composiciones de alcoxicarboxamidas microbiocidas y fungicidas y su preparacion
CO6321288A2 (es) Sales de compuestos inhibidores de vih
UY35236A (es) Compuestos de [1,2,4]triazol e imidazol sustituidos
UY33179A (es) Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2,5-sustituido.
UY31972A (es) Derivados anticancerosos, su preparación y su aplicación en terapéutica
UY33181A (es) Derivados de oxazolopirimidina 2,5-sustituidos.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200813